Articles On Neuren Pharmaceuticals (ASX:NEU)

Highlights The ASX 200 benchmark index closed in the red today (December 28), losing 32.30 points or 0.45% to end at 7,075.40 points. Over the last five days, the index has lost 0.56% and 4.65% over the last 52 weeks. Healthcare was t...

Good news is bad news for the US economy Aussie benchmark goes deep into a pre-Christmas shame spiral Ho ho oh s%#$! What just happened?   The Closing Jingle Bell has rung, so that’s it until after Christmas for 2022! What a pity today’s...

Neuren Pharmaceuticals (NEU) submits an investigational new drug (IND) application for its NNZ-2591 treatment for Prader-Willi syndrome The new IND was submitted to the US Food and Drug Administration (FDA) on December 22 for approval to...

Warrego Energy puts out initial substantial shareholder notice for Gina Rinehart entities following takeover bid Whitehaven Coal finishes November with a new substantial shareholder as two of its directors sell down holdings Neuren Pharma...

ASX Health sector is continuing its upward trend, marginally up this week 0.87%  Sonic Healthcare announces a plan to acquire ~20% holding of Microba Life Sciences Mayne Pharma shares takes a hit after company warns it won’t hit positive e...

ASX health stocks have been out of favour this year with rotation away from growth to value sector Morgan’s Scott Power said a lot of biotechs aren’t able to convert their complex science into layman’s terms Hot money going to lithium and...

The All Ordinaries Index (ASX: XAO) is kicking off this Tuesday’s session on a very positive note so far. At the time of writing, the All Ords has gained a healthy 0.4%, putting it back over 7,375 points. But for some ASX all Ords shares,...

The All Ordinaries Index (ASX: XAO) is down in the dumps on Thursday. But not all shares that call the benchmark index home are trading in the red. These three have defied the sell-off to trade at their highest points in years. Right now,...

Neuren Pharmaceuticals (NEU) receives a US$10 million (A$16 million) milestone payment from its partner, Acadia PharmaceuticalsThe payment follows the US FDA’s acceptance for review of Acadia’s new drug application for trofinetide, which wo...

Neuren Pharmaceuticals (ASX:NEU) has received the milestone payment of US$10 million from its US partner Acadia Pharmaceuticals.

Welcome back class to Part 2 of our Clinical Trials 101. When it comes to healthcare and life sciences investing there is one area where investors should take notice and that is research and clinical trials.  An understanding of how the tri...

The S&P/ASX 200 Index (ASX: XJO) is having a day to forget on Wednesday. In afternoon trade, the benchmark index is down 2.4% to 6,843.4 points. Four ASX shares that have managed to avoid the selloff and push higher today are listed...

The S&P/ASX 200 Index (ASX: XJO) is on form again on Tuesday. In afternoon trade, the benchmark index is up 0.7% to 7,010.9 points. Four ASX shares that are climbing more than most today are listed below. Here’s why they are pushing...

Neuren Pharmaceuticals (NEU) receives priority review for a New Drug Application (NDA) of its trofinetide drug for the treatment of Rett syndromeThe US Food and Drug Administration (FDA) granted the priority review and also assigned a Presc...

Acting out your dreams could be a sign of a neurological disease, a study finds ASX-listed Pharmaxis to launch a study on iRBD patients who are at risk of Parkinson’s Stockhead reaches out to Pharmaxis CEO, Gary Phillips A rare sleep diso...

The All Ordinaries Index (ASX: XAO) has been in a pendulum swing over the ASX reporting season. Here are three ASX healthcare companies that have gone under the radar. Regis Healthcare Ltd (ASX: REG) The Regis share price only lifted 0.3...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in health and gives his ASX Powerplays. Several ASX health stocks have...

Neuren Pharmaceuticals (ASX:NEU) has announced its Phase 2 clinical trials of NNZ-2591 in children with each of Phelan-McDermid syndrome and Pitt Hopkins syndrome are open for enrolment.

Neuren Pharmaceuticals (ASX:NEU) has announced its Phase 2 clinical trials of NNZ-2591 in children with each of Phelan-McDermid syndrome and Pitt Hopkins syndrome are open for enrolment.

Highlights Neuren Pharmaceuticals (ASX:NEU) has began recruiting subjects for Phase 2 clinical trials of its second drug candidate, NNZ-2591. The trials will be conducted in children each for Pitt Hopkins syndrome (PTHS) and Phelan-McD...

Highlights Neuren Pharmaceuticals (ASX:NEU) has began recruiting subjects for Phase 2 clinical trials of its second drug candidate, NNZ-2591. The trials will be conducted in children each for Pitt Hopkins syndrome (PTHS) and Phelan-McD...

Acrux and Lumos are waiting for FDA’s approvals Paradigm will present Phase 2 results Neuren commences Phase 2 trials Acrux (ASX:ACR) says the FDA has accepted its application for a generic version of coldsore treatment, ‘Acyclovir Cream,...

Neuren Pharmaceuticals (NEU) opens enrolment for phase two neurological clinical trials of its drug candidate NNZ-2591 The study is for children with Phelan-McDermid syndrome (PMS) and Pitt Hopkins syndrome (PTHS), with the first trials sc...

Highlights:  WHO has declared Monkeypox a global health emergency as cases have surfaced in 74 countries sofar. In Australia, so far, 44 confirmed cases of Monkeypox have been confirmed. Monkeypox is a disease that causes rash turning...

Highlights:  WHO has declared Monkeypox a global health emergency as cases have surfaced in 74 countries sofar. In Australia, so far, 44 confirmed cases of Monkeypox have been confirmed. Monkeypox is a disease that causes rash turning...

Highlights The Australian share market ended on a positive note on Wednesday. The ASX 200 advanced 23%, or 15.90 points to end at 6,823.20 points. The ASX All Ordinaries index finished 0.18%, or90 points higher, to close at...

Highlights The Australian share market ended on a positive note on Wednesday. The ASX 200 advanced 23%, or 15.90 points to end at 6,823.20 points. The ASX All Ordinaries index finished 0.18%, or90 points higher, to close at...

The All Ordinaries Index (ASX: XAO) is down a slender 0.04% in late afternoon trading, having made up some larger earlier losses following the release of Australia’s latest inflation figures. Within the index of top 500 stocks, three ASX...

What are the risks of investing in biotechs? How to value a biotech Top 10 crucial trials coming up for ASX biotechs in 2022 Risks of investing in biotechs Historical data shows that biotech is one the best sectors to put your money in ov...

MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s hot, their top picks, and what they’re looking out for. Today we hear from Pac Partners...

A major milestone for Australian company Neuren Pharmaceuticals (ASX:NEU) with its US partner Acadia submitting trofinetide to the FDA for the treatment of Rett syndrome.

Neuren Pharmaceuticals (NEU) submits a new drug application (NDA) to the US FDA for its Rett syndrome treatment through its partner, Acadia Pharmaceuticals If the NDA is approved by the FDA, Neuren expects to earn revenue over 2022 and 202...

HeraMED’s device is effective for telemedicine in monitoring pregnant women Mesoblast issues strong study results OncoSil announces success in Spain Just-released results from a clinical trial undertaken by Israel’s Sheba Medical Center c...

Mach 7 announces patent infringement lawsuit settled in its favour Lumos Diagnostics tanks after device submission for FebriDX rejected by US FDA Three companies announce major milestones in clinical trials Healthcare and life sciences e...

Neuren Pharmaceuticals (ASX: NEU) has announced that its Phase 2 clinical trial of NNZ-2591 in Angelman syndrome (AS) is open for enrolment.

Neuren Pharmaceuticals (NEU) opens its Phase Two clinical trial of its NNZ-2591 drug in Angelman syndrome (AS) for enrollment The trial is being conducted at three hospitals in Brisbane, Melbourne and Sydney under an investigational new dr...

Neuren’s Phase 2 clinical trial is now open for enrolment Neuroscientific submits an ethics approval request for Phase 1 trial Cannabis play Little Green Pharma signs $2m supply deal Neurological disorders specialist Neuren Pharmaceutical...

ShareCafeEvening Report: 8 July, 2022 by Lauren Evans   The Australian sharemarket had its best week since mid-March as recession fears eased. Friday’s session was spent in positive territory thanks to strong gains in the resources space. E...

Neuren Pharmaceuticals (NEU) appoints Liza A Squires to the new position of Chief Medical Officer in the United States Dr Squires is a physician in general paediatrics and neurology with special competence in child neurology Over the past...

Highlights Firebrick secures patent in Malaysia for Nasodine® Nasal Spray as a treatment and preventative for common cold Nasodine is now protected in 26 countries, with China, Singapore, Japan, and Canada on the pending list Nasodine...

Highlights The benchmark index ASX200 was 0.037% lower at 7146.200 points at 11:10 AM AEST today. Seven sectors were seen trading in the red in the early morning trading hours on Tuesday (24 May). The losses were led by the informatio...

Highlights Neuren Pharmaceuticals focuses on developing new drug therapies for serious neurological disorders Trofinetide and NNZ-2591 are two new drug candidates for Neuren The Neuren share price has gained nearly 197% over the last...

Megaport gets support of major investment firms increasing holdings Gold Road Resources increases stake in DGO Gold as part of takeover offer Milford Asset Management shows confidence in Neuren Pharmaceuticals Trading Places is Stockhead...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 24 years, explains what the movers and shakers have been doing in ASX health stocks. Good news for coffee lovers, particularly those w...

Neuren Pharmaceuticals (ASX:NEU) has received US FDA approval to proceed with the Phase 2 trial of NNZ-2591 in Pitt Hopkins syndrome.

Highlights The Australian healthcare sector includes companies engaged in biotechnology and research, food and drug retailing, health care equipment, service providers, and pharmaceuticals. On a YTD basis, the healthcare index is runni...

Highlights The benchmark ASX 200 was trading 0.15% up at 7,409.8 in the first 15 minutes of trading. The energy sector is down amid a retracement in crude oil prices. Premier Investments has declared a record interim dividend of 46 ce...

Neuren Pharmaceuticals (NEU) has approval from the US Food and Drug Administration (FDA) to proceed with Phase 2 trials of its NNZ-2951 drug, which is used to treat Pitt Hopkins syndrome Neuren has also recently received FDA approval to pr...